Where the mon­ey is, Part Two: The top cities and re­gions for biotech VC in­vest­ments

Make no mis­take about it. De­spite an­oth­er big show­ing for the Bay Area in the ros­ter of VC deals that de­liv­ered in 2016, Cam­bridge/Boston was the clear leader in the US last year, ac­cord­ing to the lat­est tal­ly of 2016 num­bers by Thom­son Reuters.

There’s long been a ri­val­ry be­tween the two coasts when it comes to in­vest­ing in the life sci­ences. And if you in­clude the three key hub cities in Cal­i­for­nia, adding num­ber 3 play­er San Diego, the West Coast con­tin­ues to dom­i­nate the field. But the con­flu­ence of acad­e­mia, VC cash, big phar­ma mi­gra­tions and big sci­ence has made Cam­bridge the epi­cen­ter of new biotech in­vest­ments glob­al­ly.

And signs look good for the trends on dis­play in the charts be­low to con­tin­ue to play out in 2017. While the IPO win­dow has par­tial­ly closed, VCs con­tin­ue to land record new funds for added in­vest­ing.

As we saw re­flect­ed in yes­ter­day’s list of the top 100 VCs, the rest of the US tends to pale in com­par­i­son when you look out­side of Cal­i­for­nia and Mass­a­chu­setts while ex­am­in­ing the flow of bil­lions of dol­lars in­to the in­dus­try. But we can’t ig­nore one big change: New York City now comes in right be­hind San Diego. And with new city and state ini­tia­tives aimed at smooth­ing off some of the Big Ap­ple’s rough edges, New York may be poised to com­pete with San Diego for the num­ber 4 spot among the cities.

It’s al­ready num­ber 4 among the key re­gions tracked by Thom­son Reuters, up from the 7th spot in 2015, with a big in­crease in cash and deals. If that trends hold true, New York may have a long way to go in catch­ing up to ei­ther Boston or the Bay Area, but there’s no mis­tak­ing its rise in­to the mid­dleweight cat­e­go­ry. And that has some big im­pli­ca­tions for in­vest­ment pat­terns in the biotech world to come.